期刊
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
卷 36, 期 4, 页码 355-371出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0000000000000523
关键词
adherence; antipsychotic; schizophrenia; bipolar disorder
资金
- Spanish Government
- FEDER [PI12/02077, PI11/01977, PI14/01900]
- Basque Foundation for Health Innovation and Research (BIOEF)
- Networking Center for Biomedical Research in Mental Health (CIBERSAM)
- University of the Basque Country [GIC12/84]
- Stanley Research Foundation [03-RC-003]
- Almirall
- AstraZeneca
- Bristol-Myers Squibb
- Cephalon
- Eli Lilly
- Glaxo-Smith-Kline
- Janssen-Cilag, Jazz
- Johnson Johnson
- Lundbeck
- Merck
- Otsuka
- Pfizer
- Sanofi-Aventis
- Servier
- Shering-Plough
- Solvay
- Spanish Ministry of Science and Innovation (CIBERSAM)
- Ministry of Science (Carlos III Institute)
- Basque Government
- Stanley Medical Research Institute
- Wyeth
- AB-Biotics
- Actavis
- Allergen
- Ferrer
- Forest Research Institute
- Gedeon Richter
- Janssen
- Roche
- Shire
- Sunovion
- Takeda
- Telefonica
- Brain and Behaviour Foundation
- Spanish Ministry of Economy and Competitiveness (CIBERSAM) [PI 12/00910]
- Seventh European Framework Programme (ENBREC)
- Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya [2014 SGR 398]
- Aequus
- Adamed
- Alexza
- Bial
- Dainippon Sumitomo Pharma
- Elan
- Eli Lily
- Gedeon Ritcher
- Novartis
- Organon
- Pierre-Fabre
- Qualigen
- Sumitomo Dainippon
- Telenofica
- Teva
- United Biosource Corporation
Antipsychotics are the drugs prescribed to treat psychotic disorders; however, patients often fail to adhere to their treatment, and this has a severe negative effect on prognosis in these kinds of illnesses. Among the wide range of risk factors for treatment nonadherence, this systematic review covers those that are most important from the point of view of clinicians and patients and proposes guidelines for addressing them. Analyzing 38 studies conducted in a total of 51,796 patients, including patients with schizophrenia spectrum disorders and bipolar disorder, we found that younger age, substance abuse, poor insight, cognitive impairments, low level of education, minority ethnicity, poor therapeutic alliance, experience of barriers to care, high intensity of delusional symptoms and suspiciousness, and low socioeconomic status are the main risk factors for medication nonadherence in both types of disorder. In the future, prospective studies should be conducted on the use of personalized patient-tailored treatments, taking into account risk factors that may affect each individual, to assess the ability of such approaches to improve adherence and hence prognosis in these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据